July 9, 2024- DiaCarta, Inc. (“DiaCarta”) has established a strategic collaboration with Capstone Health Alliance. This new collaboration brings together powerful technologies to enhance patient care. DiaCarta’s key product portfolio includes its trailblazing RadTox™ test, a blood test that monitors tumor response & progression following cancer treatment by monitoring changes in cell free circulating DNA (cfDNA) levels. This serves to personalize radiation and chemotherapy, mitigate adverse events, and enhance patient care. The state of Florida has deployed the RadTox™ test statewide to be performed between Radiotherapy or Chemotherapy doses for real time detection of treatment response or resistance.
The Oncuria bladder cancer tests are designed for the detection of bladder cancer, monitoring of bladder cancer recurrence, and revolutionizing the prediction of BCG therapy response for non-muscle invasive bladder cancer (NMIBC) patients, empowering clinicians with personalized treatment strategies. The VEXAS syndrome test is a groundbreaking, highly sensitive test that is used to diagnose a rare autoimmune condition that causes inflammation throughout the body caused by a mutation in the UBA1 gene. The ColoScape™ Colorectal Cancer Mutation Detection Blood Test detects methylations highly specific to CRC and associated genetic mutations with high sensitivity to advanced adenomas.